The combination of dasatinib and MRTX849 resulted in greater growth inhibition than either treatment alone across 11 KRAS-G12C–mutant NSCLC cell lines (SW873, H358, HCC44, HCC4019, DFCI024, HCC2122, H1373, H1792, H2030, HOP62, and UM-UC-3). Here, KRAS is linked to non-small cell lung carcinoma.